当前位置:首页 - 行情中心 - 锦波生物(920982) - 财务分析 - 现金流量表

锦波生物

(920982)

  

流通市值:95.91亿  总市值:201.01亿
流通股本:5490.51万   总股本:1.15亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金405,889,896.041,719,652,110.941,336,271,300.35882,163,806.93
  收到其他与经营活动有关的现金12,166,278.7464,197,483.0844,272,434.7226,068,727.36
  经营活动现金流入小计418,056,174.781,783,849,594.021,380,543,735.07908,232,534.29
  购买商品、接受劳务支付的现金36,937,519.67186,092,420.47125,168,020.0186,109,816.26
  支付给职工以及为职工支付的现金75,257,815.35269,313,846.67206,071,312.61140,982,333.25
  支付的各项税费52,202,181.81326,124,778.06231,084,952.12130,992,069.68
  支付其他与经营活动有关的现金90,609,161.58372,316,358.83263,996,231.13167,442,865.34
  经营活动现金流出小计255,006,678.411,153,847,404.03826,320,515.87525,527,084.53
  经营活动产生的现金流量净额163,049,496.37630,002,189.99554,223,219.2382,705,449.76
二、投资活动产生的现金流量:
  收回投资收到的现金800,000,0002,400,000,0001,650,000,0001,050,000,000
  取得投资收益收到的现金2,052,393.986,278,637.94,889,164.882,885,501.07
  处置固定资产、无形资产和其他长期资产收回的现金净额-900--
  投资活动现金流入小计802,052,393.982,406,279,537.91,654,889,164.881,052,885,501.07
  购建固定资产、无形资产和其他长期资产支付的现金35,232,150.81370,322,228.53279,959,008.52223,492,946.32
  投资支付的现金800,000,0002,430,700,0001,680,000,0001,050,000,000
  投资活动现金流出小计835,232,150.812,801,022,228.531,959,959,008.521,273,492,946.32
  投资活动产生的现金流量净额-33,179,756.83-394,742,690.63-305,069,843.64-220,607,445.25
三、筹资活动产生的现金流量:
  吸收投资收到的现金1,000,0008,900,0005,900,0001,000,000
  其中:子公司吸收少数股东投资收到的现金1,000,0008,900,0005,900,0001,000,000
  取得借款收到的现金-143,000,000--
  收到其他与筹资活动有关的现金-3,500,0003,500,0003,500,000
  筹资活动现金流入小计1,000,000155,400,0009,400,0004,500,000
  偿还债务支付的现金3,500,00037,801,12921,310,17114,510,171
  分配股利、利润或偿付利息支付的现金1,279,713.19294,520,199.19294,019,083.36178,371,660.86
  支付其他与筹资活动有关的现金1,190,263.87,183,971.454,574,478.92,545,223.74
  筹资活动现金流出小计5,969,976.99339,505,299.64319,903,733.26195,427,055.6
  筹资活动产生的现金流量净额-4,969,976.99-184,105,299.64-310,503,733.26-190,927,055.6
四、汇率变动对现金及现金等价物的影响-121,397.27-131,991.98-56,021.17-15,387.4
五、现金及现金等价物净增加额124,778,365.2851,022,207.74-61,406,378.87-28,844,438.49
  加:期初现金及现金等价物余额992,146,971.14941,124,763.4941,124,763.4941,124,763.4
  期末现金及现金等价物余额1,116,925,336.42992,146,971.14879,718,384.53912,280,324.91
补充资料:
  净利润-645,710,506.58-390,711,169.36
  资产减值准备-23,085,134.39-10,822,324.14
  固定资产和投资性房地产折旧-56,661,582.85-26,499,849.13
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-56,661,582.85-26,499,849.13
  无形资产摊销-11,700,720.56-5,538,288.21
  长期待摊费用摊销-4,094,206.3-2,022,549.32
  固定资产报废损失-1,635,495.87-1,597,779.02
  财务费用-7,519,786.63-4,013,704.39
  投资损失--6,176,174.86--2,885,501.07
  递延所得税--4,626,236.92--2,323,172.27
  其中:递延所得税资产减少--4,336,593.8--2,178,350.71
    递延所得税负债增加--289,643.12--144,821.56
  存货的减少--94,383,162.15--58,252,088.1
  经营性应收项目的减少--72,102,365.54--85,381,813.26
  经营性应付项目的增加-38,610,817.78-70,607,697.84
  其他--3,862,298.89-9,196,955.8
  不涉及现金收支的投资和筹资活动金额其他项目-5,512,327.31--
  现金的期末余额-992,146,971.14-912,280,324.91
  减:现金的期初余额-941,124,763.4-941,124,763.4
  现金及现金等价物的净增加额-51,022,207.74--28,844,438.49
公告日期2026-04-292026-04-292025-10-292025-08-11
审计意见(境内)标准无保留意见
TOP↑